As part of Operation Pangea, over 3 million illegally traded medicines and medical devices have been seized as part of a global crackdown. The products were valued at over £9 million. Operation Pangea was originally instigated by the Medicines and Healthcare products Regulatory Agency (MHRA), it is also coordinated by INTERPOL. Operation Pangea is a well-established international effort to disrupt the online sale of counterfeit and illicit health products. Just as importantly, Pangea works...

Business Secretary Kwasi Kwarteng has announced his preferred selection for the chair of UK Research and Innovation (UKRI). Sir Andrew Mackenzie will be tasked with driving forward the Government’s ambitious goals for UK research and innovation. Sir Andrew has a background in both science and business areas. His early career was as an academic geochemist, then moved into industry and was the Chief Executive of BHP (a mining company).Sir Andrew is now Company Chair of Shell and was knighted...

BIVDA responds to G7 Communique on antimicrobial resistance (AMR) BIVDA has responded to the communique published by the attendees at the G7 meeting in Cornwall, pledging to do more to tackle the problem of AMR. Across the world, AMR is responsible for hundreds of thousands of avoidable deaths a year and the numbers are increasing year on year by 4% - and will continue to do so as current antibiotics lose their effectiveness against new and evolving strains of bacteria.  Commentin...

A clinically-led review of urgent and emergency care standards has been published by NHS England. The new report has been welcomed by health organisations, patients, clinicians and the public. Findings included in the review have led to recommendations on the reduction of hidden waiting times, the lowering of COVID-19 risks in health settings.  The overall objective of the standards review as to recognise what was clinically important to patients. The review was based on a consultation on t...

BIVDA offers industry support to Government for COP26 climate goals BIVDA, the trade association for in-vitro diagnostic companies, has written to the President of COP26, Alok Sharma MP, to offer the support of the industry for the forthcoming COP26 summit in Glasgow. BIVDA and its members have been at the forefront of our response to the pandemic, working closely with colleagues at NHS England the Department for Health and Social Care during this challenging period. As part of this cr...

According to a new market research report from MarketsandMarkets, the infectious disease diagnostics market could be worth $39.8 billion by 2026. Growing awareness for early disease diagnosis, the prevalence of infectious diseases worldwide and onset of COVID-19 are factors supporting the high growth of this particular market. The infectious disease market is segmented into reagents, kits and consumables, instruments, software and services. The reagents, kits, and consumables segment accounted f...

BIVDA helped to formulate the new NICE Diagnostic Pathology Impact Report and we welcome its publication – we look forward to working with NICE and NHS England stakeholders on making even more progress to improve services.Our External Affairs team has produced a briefing on the report, highlighting its recommendations and future action for engaging with stakeholders, including BIVDA.Links to reports cited in the briefing are as follows:Early Detection and Diagnosis of Cancer RoadmapTh...

£30 million is to be invested in postgraduate training courses for doctors, to ensure the NHS has access to skills necessary in managing the patient care backlog from the pandemic. Many postgraduate trainees have postponed their study in order to work on the frontline. This funding will be manifested in a tailored approach, based on the individual needs of trainees, including one-to-one training conversations and recovery plans. As many as 123,800 doctors and over 303,000 nurses are now wo...

BIVDA Digital Working Party Reminder Register here.  10:30     Welcome, introductions and competition law      10.35     Overview of the IVD development pathway and how CPI can help commercialise digital IVD devices using their in-house capabilities and expertise          UK CPI (catapult)10.55   Digital Revolution Industry paper final drafting Helen Dent, BIVDA11.35&...

Press Release                                                                                 &...